Gerald said that there is no such test exists that gives higher sensitivity and specificity for MS diagnosis and MS-Precise will control the market with 300 mil initial revenue projection. Now JN says exactly opposite.. Don't know who is right but there is severe misdiagnosis reported and the treatments available for MS have significant side effects and that is the main reason there is need for accurate diagnosis...
I don't know which one is cheaper but AMBS is investigating options that MS diagnosis to be blood based. If that happens it will be cheaper option for sure.
The reason they are evaluating blood based biomarkers for MS is that now they have acquired Georgetown assays which identifies biomarkers for Alz. They have acquired exclsive option for Lipids and Exosomes.
The MS diagnosis involve scan of Cerebral spinal fluid (CSF). Exosomes have CD81 biomarker that relates to CSF but it is blood based so I think they would be able to identify blood based biomarkers for MS.
News 
Market Data 
Discover 
